ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Rationale: Overexpression of epidermal growth factor receptor (EGFR) has been observed in
kidney, prostate, colon, lung, breast, and other cancers, and is often associated with a poor
prognosis. TGFa and EGF, the ligands for EGFR, are also overexpressed in some of these tumor
types, suggesting a self-propagating stimulus that may be responsible for rapid tumor growth.
Blocking this stimulus by blocking activation of EGFR with ABX-EGF, a fully human monoclonal
antibody against EGFR, may prevent tumor growth and perhaps shrink tumors. Purpose: This is a
Phase 2 clinical trial to evaluate the safety and efficacy of ABX-EGF in combination with
paclitaxel and carboplatin in the treatment of advanced NSCLC.